Conditions We Help Coordinate CAR-T Treatment For
China's NMPA has approved CAR-T cell therapies across four cancer types. Each has its own eligibility criteria, approved products and typical journey — choose yours below for the full detail.
Lymphoma
Relapsed/refractory large B-cell lymphoma (incl. DLBCL), high-grade B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
Full details →Leukemia (B-ALL)
Relapsed/refractory B-cell acute lymphoblastic leukemia in adults, and ages 3–21 for one approved product.
Full details →Multiple Myeloma
Relapsed/refractory multiple myeloma after at least three prior lines of therapy.
Full details →Gastric & Solid Tumors
Advanced CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
Full details →Not sure which applies to you?
Send us your pathology report and we will tell you which approved products, if any, match your diagnosis — as part of your free medical record review. Start here →